Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy

Watch on YouTube ↗  |  January 13, 2026 at 13:48  |  8:50  |  CNBC
Speakers
Chris Viehbacher — President and Chief Executive Officer, Biogen Inc.
Becky Quick — Co-Anchor, Squawk Box

Summary

Biogen CEO Chris Viehbacher spoke at the JPMorgan Healthcare Conference about Biogen's 2026 pipeline, rare-disease strategy, and the broader biotech outlook. He highlighted five potentially transformative medicines, ten late-stage registrational trials, and rare-disease programs with global commercialization potential. He also said the biopharmaceutical sector is returning to an upswing as capital conditions improve and interest rates fall.

  • Biogen sees 2026 as a catalyst-rich year with five potentially transformative medicines and ten late-stage registrational trials.
  • The company is focused on rare diseases, citing large unmet need, global patient reach, and government reimbursement.
  • Spinraza's global patient base and the Friedreich's ataxia program illustrate Biogen's rare-disease economics.
  • Biogen's multiple sclerosis experience is expected to help a new lupus medicine in a larger disease area.
  • The CEO said biopharma is coming back into an upswing after COVID-era overfunding and higher failure rates.
  • Lower interest rates, reopened venture capital, and capital rotation into innovation are supporting biotech.
  • Tariffs, most-favored-nation pricing, and European pricing discussions remain key macro and regulatory issues.
Ideas
Chris Viehbacher President and Chief Executive Officer, Biogen Inc. 0:34
Pipeline catalysts drive sustainable growth
Biogen is entering an important catalyst-rich period. The company says it has five potentially transformative new medicines, three in rare diseases, and ten late-stage registrational clinical trials. 2026 is when it starts to turn over those cards, with new studies expected each year that could lead to registrations and a future of sustainable growth after launching first-in-class and first-in-disease medicines.
BIIB HIGH
Chris Viehbacher President and Chief Executive Officer, Biogen Inc. 1:53
Rare disease market has global unmet need
Rare diseases are a major healthcare opportunity despite small individual patient populations: about 10,000 rare diseases affect roughly 10% of the population, diagnosis is difficult, and products can be globalized. Spinraza has about 15,000 patients worldwide, 9,000 outside the U.S. Low operating costs and government willingness to pay for unmet need can support programs like Friedreich's ataxia at $1B-$1.5B, and rare-disease capabilities can transfer to complex non-rare diseases such as lupus.
Rare disease therapeutics HIGH
Chris Viehbacher President and Chief Executive Officer, Biogen Inc. 7:04
Biotech sector entering new upswing
The biopharmaceutical/biotech sector is coming back into an upswing. COVID-era overfunding created weak companies and high failure rates, but the remaining companies have solid data and can raise capital. Lower interest rates help a long-duration drug-development industry, venture capital is opening, capital is rotating from tech and other healthcare areas into innovation, and European pricing discussions may narrow U.S.-Europe pricing gaps.
XBI HIGH
Up Next
6:43
Nouriel Roubini Sees a Tech-Led US ‘Productivity Revolution’
Bloomberg Markets · Jan 13
9:34
Tom Rogers on the battle over WBD: It doesn't really matters who ends up winning this fight
CNBC · Jan 13
23:07
Property Play: Data center CEO says, 'You can't build it fast enough'
CNBC · Jan 13
6:15
Rep. Pfluger on GOP’s reconciliation 2.0: It’s time for Congress to codify what Pres. Trump has done
CNBC · Jan 13
5:11
China's economy isn't very good, but 'is good enough for Xi': China Beige Book CEO Leland Miller
CNBC · Jan 13

This CNBC video, published January 13, 2026, features Chris Viehbacher discussing BIIB, Rare disease therapeutics, XBI. 3 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Chris Viehbacher  · Tickers: BIIB, Rare disease therapeutics, XBI